Study Assesses Diagnostic Accuracy of Biomarkers in Alzheimer’s Dementia
In a study of biomarkers in Alzheimer’s dementia, plasma p-tau217 had greater agreement with CSF and amyloid-PET biomarker profiles than did FDG-PET scans.
Read More
Search Physician’s Weekly
Search for articles, editorials, meeting coverage, podcasts, and more
Showing 1 - 20 of 127 results for 'Alzheimer’s dementia'
How to Help Caregivers of Patients With Dementia
Dr. Linda Girgis discusses the many ways physicians can assist caregivers of patients with dementia, helping them to avoid experiencing burnout.
Read More
Enhancing Dementia Research Through Cohort Collaboration and Federated Analysis
The following is a summary of “Identifying pathways to the prevention of dementia: the Netherlands...
Read More
Simple Tools to Improve Your Delivery of Dementia Diagnosis
Joanna Paladino, MD, and colleagues identified four themes that may improve the delivery of a dementia diagnosis for clinicians, patients, and caregivers.
Read More
Tau Deposition in Praxis-Related Brain Regions and Apraxia in Alzheimer’s Disease
The following is a summary of “Cortical Tau Aggregation Patterns Associated With Apraxia in...
Read More
Caregivers of people with dementia may benefit from online decision aid when managing firearm access
1. In this randomized controlled trial involving caregivers for people with Alzheimer’s disease...
Read More
Demographics, Smell Test, and Cognitive Test Can Predict Cognitive Decline, Dementia
MONDAY, Oct. 21, 2024 (HealthDay News) — Impairment in both an odor identification test and...
Read More
Using the DemRisk prediction model to indentify individuals at high risk for dementia in primary care
1. Predicting dementia in primary care settings for a 60-79 year old cohort should include age,...
Read More
Cerebral Small Vessel Disease Links Vascular Risk Factors to Alzheimer’s Pathology
The following is a summary of “Association of vascular risk factors and cerebrovascular pathology...
Read MoreAdvertisement
Hormone-modulating therapy decreased risk of dementia in breast cancer patients
1. In a retrospective cohort study of women newly diagnosed with breast cancer, use of hormone...
Read More
APOE3 Christchurch heterozygosity may delay cognitive impairment in Alzheimer’s disease
1. Carriers of the E280A variant of presenilin 1 (PSEN1E280A) who were heterozygous for the...
Read More
Analyzing Dementia Progression from MCI in T2D through OH Acceleration
The following is a summary of “Orthostatic Hypotension Promotes the Progression From Mild...
Read More
Understanding Alzheimer’s Fluid Biomarker Variability in Memory Clinic Patients Without Dementia
The following is a summary of “Explaining the Variability of Alzheimer Disease Fluid Biomarker...
Read More
Exploring Microglial Activation, β-Amyloid, Metabolism, and Cortical Thickness in Adults without Dementia
The following is a summary of “Association of β-Amyloid, Microglial Activation, Cortical...
Read More
CSF NPTX2 Changes and Their Link to Brain Metabolism in Alzheimer’s Mild Cognitive Impairment
The following is a summary of “Cerebrospinal fluid NPTX2 changes and relationship with regional...
Read MoreΒ-amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older
The following is a summary of “Association Between β-Amyloid Accumulation and Incident Dementia in Individuals 80 Years or Older Without Dementia,” published in the December 2023 issue of Neurology by Lopez et al. Despite...
Read More
Twin’s Dementia Tied to Shorter Life Expectancy in Unaffected Twin
TUESDAY, Dec. 19, 2023 (HealthDay News) — Shared genes and environment can lead twins with...
Read MoreDoubts Abound About a New Alzheimer’s Blood Test
For the first time, people worried about their risk of Alzheimer’s disease can go online, order a blood test, and receive results in the privacy of their homes. This might seem appealing on the surface, but the development...
Read MoreNew Alzheimer’s Drug Raises Hopes — Along With Questions
The FDA has approved Leqembi, the first disease-modifying treatment for early-stage Alzheimer’s and a precursor condition, mild cognitive impairment. Medicare has said it will pay for the therapy. Medical centers across...
Read MoreThe Real Costs of the New Alzheimer’s Drug, Most of Which Will Fall to Taxpayers
The first drug purporting to slow the advance of Alzheimer’s disease is likely to cost the U.S. health care system billions annually even as it remains out of reach for many of the lower-income seniors most likely to...
Read More